Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Methods of using sIP-10, CD26 inhibitors and CXCR3 levels in a sample to assess clearance of infection, response to interferon therapy, and treating chronic infections

Methods of using sIP-10, CD26 inhibitors and CXCR3 levels in a sample to assess clearance of infection, response to interferon therapy, and treating chronic infections

US Patent 8124332 · Granted Feb 28, 2012

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Diagnostic and therapeutic methods for cancer2024
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both2024
Anti-CD8 antibodies and uses thereof2023
Thermochromic polymeric nanocomposites and methods of making same2023
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both2022
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both2021
Levels of CXCL10/IP-10 forms and soluble CD26/DPPIV activity as early predictive2019
Levels of CXCL 10/IP-10 forms and soluble CD26/DPPIV activity as early predictiv2016
Methods for use of apoptotic cells to deliver antigen to dendritic cells for ind2011
Methods of using sIP-10 to assess HCV clearance and/or response to interferon th2010
Methods of using sIP-10 to assess HCV clearance and/or response to interferon th2010
Methods of using sIP-10 to assess HCV clearance and/or response to interferon th2010